Human IL-9 Antibody - Enokizumab Biosimilar

Human IgG1 - CAS #909875-08-7

ABOUT

Anti-human IL-9 - Enokizumab biosimilar - CAS #909875-08-7

Anti-hIL-9-hIgG1 is a biosimilar antibody of Enokizumab, a human interleukin 9 (IL-9) antibody that inhibits IL-9 signaling. This monoclonal antibody (mAb) is currently under investigation for the treatment of asthma, atopic dermatitis, and inflammatory bowel diseases (IBD).

More details More details

 

Anti-hIL-9-hIgG1 comprises the variable region of Enokizumab and the IgG1 constant region of Enokizumab for high effector functions. 

This mAb can be used together with HEK-Blue™ IL-9 cells for screening and neutralization assays to inhibit IL-9 signaling induced by recombinant human IL-9 (see figure).

 

Key features

  • Each lot is functionally tested and validated.
  • The complete sequence of the antibody construct was verified.
  • The absence of endotoxins is determined using the EndotoxDetect™ assay.

All products are for research use only, and not for human or veterinary use.

Binding of anti-IL-9 mAb
Binding of anti-IL-9 mAb

SPECIFICATIONS

Specifications

Target

IL-9

Target species

Human

Isotype
hIgG1
kappa
Recommended isotype control
Human IgG1 Isotype Control Antibody
Clone
Enokizumab
CAS number
909875-08-7
Synonyms
7F3com-2H2
MEDI-528
Molecular weight
145.8 kDa
Tag
Tag-free
Source
CHO cells
Production details
Animal-free
Purification
Protein A
Formulation buffer

Sodium phosphate buffer, glycine, saccharose, stabilizing agents

Preservative
Azide-free
Purity
≥ 95 %
Appearance (form)
Lyophilized
Reconstitution buffer
Sterile water (not provided)
Endotoxin

Negative (tested using EndotoxDetect™ assay)

Tested applications

Neutralization assay, ELISA

Quality control

Each lot is functionally tested and validated.

CONTENTS

Contents

  • Product: 
    Anti-hIL-9-hIgG1
  • Cat code: 
    hil9-mab1
  • Quantity: 
    100 µg

Shipping & Storage

  • Shipping method:  Room temperature

    • Storage:

    • -20 °C
    Stability: -20°C for up to 1 year

    Caution:

    • Avoid repeated freeze-thaw cycles

Details

Enokizumab and IL-9 background

Enokizumab (MEDI-528) is a humanized monoclonal antibody (mAb) designed to target interleukin 9 (IL-9) and block the IL-9 signaling [1]. 

IL-9 is a cytokine produced by a wide variety of cells including mast cells, natural killer T (NKT) cells, Th2, Th17, Treg, and Th9 cells. Th9 cells are considered to be the main CD4+ T cells that produce IL-9.  To date, its main role has been found in the immune responses against allergic diseases such as asthma and bronchial hyperreactivity. IL-9 promotes the survival, proliferation, and activation of mast cells and other immune cells, which are central to the development of allergic reactions and inflammatory diseases [2].

Enokizumab is currently being investigated for its potential therapeutic applications in various inflammatory and allergic diseases, with a particular focus on asthma, atopic dermatitis, and inflammatory bowel diseases (IBD). In asthma treatment, it has shown promise in patients with a specific IL-9-driven inflammatory profile [2-3]. Asthma, particularly in severe forms, is characterized by airway inflammation and hyperreactivity, often triggered by immune cells and cytokines like IL-9 [2-3]. However, despite the encouraging data from some trials, regulatory approval for the drug is still pending.

 

References:

1. Parker JM, et al., 2011. Safety profile and clinical activity of multiple subcutaneous doses of MEDI-528, a humanized anti-interleukin-9 monoclonal antibody, in two randomized phase 2a studies in subjects with asthma. BMC Pulm Med. 11:14.
2. Bick F, et al., 2025. A reappraisal of IL-9 in inflammation and cancer. Mucosal Immunol. (1):1-15.
3. NCT00590720: a Phase 2A Study to Evaluate the Safety and Effect on Exercise Challenge Testing of MEDI-528 in Adults With Asthma.

You may also need

CUSTOMER SERVICE & TECHNICAL SUPPORT

Question about this product ?